Two Start-ups announce drug discovery collaboration

Confo Therapeutics and DyNAbind collaborate to Identify Novel GPCR-Modulating Compounds

03-Jul-2019 - Confo Therapeutics andDyNAbind GmbH announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBody™-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under ...

Confo Therapeutics enters into drug discovery collaboration with Roche

21-Dec-2017 - Confo Therapeutics, announced that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and ...

Confo Therapeutics to appoint John Berriman as Chairman of the Board

15-Dec-2016 - Confo Therapeutics, an emerging drug discovery company, today announced the appointment of John Edward Berriman as non-executive director and chairman of the board of directors, starting December 21. Commenting on the board appointment, Dr. Cedric Ververken, CEO, said: “We are delighted to have ...

New biotech company Confo Therapeutics launched by VIB and Vrije Universiteit Brussel

Capricorn Venture Partners leads 1st financing round of € 3 million

26-Jun-2015 - The establishment of Confo Therapeutics, a spin-off of VIB and Vrije Universiteit Brussel, was announced today. A consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI contributed € 3 million in the first institutional round of investment. These resources will be ...